Filtered By:
Condition: Heart Failure
Drug: Insulin

This page shows you your search results in order of date. This is page number 14.

Order by Relevance | Date

Total 323 results found since Jan 2013.

Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999-2016
CONCLUSIONS: NAFLD is usually asymptomatic, but this large study of a large general population shows that LFS is associated with CHD, CHF, angina pectoris, cardiovascular and all-cause mortality. Determining the LFS is worthwhile, as it identifies people with NAFLD, who may also be at increased cardiovascular risk.Key MessagesLiver fat score (LFS), a non-invasive marker of non-alcoholic fatty liver disease (NAFLD), is associated with coronary heart disease (CHD), congestive heart failure (CHF) and angina.LFS is also associated with increased cardiovascular and all-cause mortality.Determining the LFS is worthwhile as it ide...
Source: Annals of Medicine - June 29, 2021 Category: Internal Medicine Authors: Chun-On Lee Hang-Long Li Man-Fung Tsoi Ching-Lung Cheung Bernard Man Yung Cheung Source Type: research

Role Of Glp-1 Analogs In The Management Of Diabetes And Its Secondary Complication
Mini Rev Med Chem. 2021 Apr 21. doi: 10.2174/1389557521666210422114909. Online ahead of print.ABSTRACTThe cardiovascular complications of type 2 diabetes mellitus (T2DM) include myocardial infarction, heart failure, peripheral vascular disease and, stroke and retinopathy, nephropathy and neuropathy are microvascular complications. While the newer therapies like glitazones or even dipeptidyl-peptidase-IV (DPP-IV) inhibitors increase the risk of therapy, the Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs), were reported as suitable alternates. The GLP-1RAs reduce the major adverse cardiovascular events (MACE), have anti...
Source: Mini Reviews in Medicinal Chemistry - April 23, 2021 Category: Chemistry Authors: Ponnurengam Malliappan Sivakumar B Premkumar Prabhawathi Veluchamy Pranav Kumar Prabhakar Source Type: research

Guideline Adherence and Associated Outcomes in the Treatment of Type 2 Diabetes Mellitus Patients With an Incident Cardiovascular Comorbidity: An Analysis Based on a Large German Claims Dataset
ConclusionOnly a minority of patients with T2DM and an incident CV comorbidity receive a treatment fully adherent with guideline recommendations. This may contribute to high mortality rates in this population in clinical practice.
Source: Diabetes Therapy - March 12, 2021 Category: Endocrinology Source Type: research

Ten-year all-cause death following percutaneous or surgical revascularization in patients with prior cerebrovascular disease: insights from the SYNTAX Extended Survival study
ConclusionPrior CEVD was associated with a significantly increased risk of 10  year all-cause death which was similar in patients treated with PCI or CABG. These results do not support preferential referral for PCI rather than CABG in patients with prior CEVD.Trial registration: SYNTAX: ClinicalTrials.gov reference: NCT00114972. SYNTAX Extended Survival: ClinicalTrials.gov reference: NCT03417050.Graphic abstract
Source: Clinical Research in Cardiology - January 30, 2021 Category: Cardiology Source Type: research

SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients.
Conclusion: SGLT2 inhibitors are novel antidiabetic medications with immense utility in the management of patients with T2DM. Furthermore, SGLT2 inhibitors have demonstrated to reduce the progression to advanced forms of kidney disease and its associated complications. These medications should be front and center in the management of patients with diabetic kidney disease with and without chronic kidney disease as they confer protection against cardiovascular/renal death and improve all-cause mortality. Future studies should evaluate the benefits and implications of early initiation of SGLT2 inhibitors, as well as the long-...
Source: International Journal of Nephrology and Renovascular Disease - November 7, 2020 Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
CONCLUSION: In diabetic patients at low cardiovascular risk, no treatment differs from placebo for vascular outcomes. In patients at increased cardiovascular risk receiving metformin-based background therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a favorable effect on certain cardiovascular outcomes. PRIMARY FUNDING SOURCE: European Foundation for the Study of Diabetes, supported by an unrestricted educational grant from AstraZeneca. (PROSPERO: CRD42019122043). PMID: 32598218 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - June 29, 2020 Category: Internal Medicine Authors: Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E Tags: Ann Intern Med Source Type: research

Cardiovascular effects of preeclampsia
This study reviews the evidence of increase cardiovascular risk in these women. Recent findings Women with preeclampsia are at two-fold higher risk for development of coronary artery disease, stroke and death, and four-fold increased risk of heart failure. Preeclampsia developed in early part of pregnancy confers greater risk than later in pregnancy. Common factors that predispose women to preeclampsia also confer high risk for developing cardiovascular disease include obesity, metabolic abnormalities, dyslipidaemia, insulin resistance, heightened inflammatory responses, hypercoagulable states and endothelia dysfunction...
Source: Current Opinion in Cardiology - June 6, 2020 Category: Cardiology Tags: HYPERTENSION: Edited by Hector O. Ventura and Carl J. Lavie Source Type: research

Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
Conclusion: Treating T2DM patients using dapagliflozin instead of conventional medications, maximizes patient's benefits and decreases total costs due to drug cost offsets from fewer cardiovascular and renal events. The adoption of dapagliflozin is a budget-saving treatment option, resulting in substantial population-level health gains due to reduced event rate and cost savings from the perspective of the national healthcare system. PMID: 32364032 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - May 5, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Obstructive sleep apnoea and cardiovascular consequences: Pathophysiological mechanisms.
Abstract Obstructive sleep apnoea syndrome is a growing health concern, affecting nearly one billion people worldwide; it is an independent cardiovascular risk factor, associated with incident obesity, insulin resistance, hypertension, arrhythmias, stroke, coronary artery disease and heart failure. Obstructive sleep apnoea-related cardiovascular and metabolic co-morbidities are a major concern for prognosis and the complexity of obstructive sleep apnoea integrated care. Continuous positive airway pressure, the first-line therapy for the treatment of obstructive sleep apnoea, is highly effective at improving sympto...
Source: Archives of Cardiovascular Diseases - March 25, 2020 Category: Cardiology Authors: Arnaud C, Bochaton T, Pépin JL, Belaidi E Tags: Arch Cardiovasc Dis Source Type: research

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Copeptin - a new diagnostic and prognostic biomarker in neurological and cardiovascular diseases.
Authors: Baranowska B, Kochanowski J Abstract Copeptin, arginine vasopressin (AVP)-associated 39 aminoacid glycopeptide, is a C-terminal part of pro-AVP. AVP acts through V1a, V1b, and V2 receptors. The effect on V1a receptors is connected with arterial vasoconstriction, on V2 with antidiuretic action, and on V1b with the secretion of ACTH, insulin, glucagon. Copeptin is found in the circulation in equimolar amounts with AVP. It is a very stable peptide and easy to estimate. Copeptin is a good diagnostic marker in many disorders in which vasopressinergic dysfunction plays a role in pathogenesis such as a polyuria-...
Source: Neuroendocrinology Letters - March 1, 2020 Category: Endocrinology Tags: Neuro Endocrinol Lett Source Type: research